世界の微小残存病変検査の市場規模は 2027 年までに14.0%のCAGRで成長し、23 億ドルに達すると予想されます。この市場で活動している主要なプレーヤーは次のとおりです：Labcorp Inc.（米国）、Hoffmann-La Roche Ltd.(スイス)、Guardant Health (米国)、シスメックス株式会社 (日本)、NeoGenomics Laboratories, Inc. (米国)、Adaptive Biotechnologies Corporation (米国)、ArcherDX, Inc. (米国)、Asuragen Inc. (米国)、Arup Laboratories Inc. (米国)、Bio-Rad Laboratories, Inc. （米国）、Cergentis B.V. (オランダ)、Molecular MD (ICON plc) (アイルランド)、Invivoscribe, Inc. (米国), Mission Bio, Inc. (米国), Natera, Inc. (米国)、Opko Health, Inc. （米国）、Quest Diagnostics（米国）、Genetron Health（中国）など
目次
Table of Content
1 Introduction
1.1 Objectives of the Study
1.2 Market Definition?
1.3 Market Scope?
1.4 Currency
1.5 Market Stakeholders?
1.6 Summary of Changes
2 Research Methodology
2.1 Research Data
2.1.1 Secondary Data
2.1.2 Primary Data
2.2 MARKET SIZE ESTIMATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 RISK ASSESSMENT
2.7 LIMITATIONS
2.8 GROWTH RATE ASSUMPTIONS
3 Executive Summary
4 Premium Insights
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.2 Restraints
5.2.3 Opportunities
5.2.4 Challenges
5.3 Pricing Analysis
5.3.1 Indicative Pricing Model Analysis
5.4 Case Study Analysis
5.5 Ranges/Scenarios
5.6 Value Chain Analysis
5.7 Supply Chain Analysis
5.8 Porter's Five Forces Analysis
5.9 Ecosystem Analysis of the Global Minimal Residual Disease Testing Market
5.10 PESTLE Analysis
5.11 Tariff & Regulatory Landscape
5.11.1 Regulatory Bodies, Government Agencies & Other Organizations
5.12 Patent Analysis
5.13 Trends/Disruptions Impacting Customers' Business
5.14 Key Conferences & Events in 2022-2023
5.15 Key Stakeholders & Buying Criteria
5.16 Technology Analysis
5.17 Trade Analysis
6 Minimal Residual Disease Testing Market, by Technology
6.1 Introduction
6.2 Flow Cytometry
6.3 Polymerase Chain Reaction
6.4 Next-Generation Sequencing
6.5 Other Technologies
7 Minimal Residual Disease Testing Market , by Application?
7.1 Introduction?
7.2 Hematological Malignancy
7.2.1 Leukemia
7.2.1.1 Myeloid Leukemia
7.2.1.2 Lymphoblastic Leukemia
7.2.1.3 Other Leukemias
7.2.2 Lymphoma
7.2.2.1 Non-Hodgkin’s Lymphoma (NHL)
7.2.2.2 Hodgkin’s Lymphoma
7.3 Solid Tumor
7.4 Other Applications
8 Minimal Residual Disease Testing Market , by End User
8.1 Introduction
8.2 Hospitals and Specialty Clinics
8.3 Diagnostic Laboratories
8.4 Academic and Research Institutes
8.5 Other End Users
9 Minimal Residual Disease Testing Market, by Region
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.3 Europe
9.3.1 Germany?
9.3.2 UK
9.3.3 France
9.3.4 Italy
9.3.5 Spain
9.3.6 RoE
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 RoAPAC
9.5 Latin America
9.6 Middle East & Africa
10 Competitive Landscape
10.1 Introduction
10.2 Key Player Strategies/Right to Win
10.3 Market Share Analysis
10.4 Revenue Share Analysis
10.5 Company Evaluation Quadrant
10.5.1 Stars
10.5.2 Emerging Leaders
10.5.3 Pervasive Players
10.5.4 Participants
10.5.5 Competitive Benchmarking
10.6 Start-up Evaluation Quadrant
10.6.1 Progressive Companies
10.6.2 Starting Blocks
10.6.3 Responsive Companies
10.6.4 Dynamic Companies
10.7 Competitive Scenario and Trends
10.7.1 Product Launches & Approvals
10.7.2 Deals
10.7.3 Other Developments
10.8 Product Footprint Analysis of Top Players
10.9 Geographic Footprint Analysis of Top Players
11 Company Profiles
11.1 Key Players
11.1.1 Adaptive Biotechnologies Corporation
11.1.2 ArcherDX, Inc.?(Invitae Corporation)
11.1.3 Asuragen
11.1.4 Arup Laboratories
11.1.5 Bio-Rad Laboratories, Inc.
11.1.6 Cergentis B.V.
11.1.7 F. Hoffmann- La Roche Ltd
11.1.8 Guardant Health
11.1.9 ICON plc
11.1.10 Invivoscribe, Inc.
11.1.11 Laboratory Corporation of America Holdings
11.1.12 Mission Bio, Inc.
11.1.13 Natera, Inc.
11.1.14 NeoGenomics Laboratories, Inc.
11.1.15 Opko Health, Inc.
11.1.16 Quest Diagnostics Incorporated
11.1.17 Sysmex Corporation
11.1.18 Genetron Health
12 Appendix
